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A premature infant is at high risk for many complications and multiple morbidities.  A 
patent ductus arteriosus (PDA) is just one complication that often presents with prematurity and 
can be a major cardiac defect creating variations of altered cardiac function and systemic 
circulation.  The severity of effects a PDA can produce depends on factors such as gestational 
age of the infant, weight of the infant, size of the defect, and the overall health of the neonate.   
This topic is significant in the medical field because infants born prematurely are seen to 
have a high rate of their patent ductus arteriosis (PDA) not closing after birth resulting in 
complications.  When the PDA does not close, it produces left to right shunting of the blood in 
the heart.  Left to right shunting is associated with pulmonary congestion and decreased blood 
flow to vital organs (Linder et al., 2010).  Prior to the introduction of ibuprofen, the only 
alternative to indomethacin was a surgical ligation.  This includes a thoracotomy with potentially 
serious complications including chylothorax, infections, respiratory compromise, and death, 
which is why this should be considered the last option (Sekar & Corff, 2008).  
Ibuprofen was introduced as an alternative medication to close the PDA, but it is not 
being utilized in all institutions.  The purpose of this project is to explore the use of ibuprofen as 
the first line of treatment for the closure of the PDA in the neonatal population.  Information 
produced could aide in the development of a new standard of care in the neonatal intensive care 
units.  Explanation of ibuprofens safety and efficacy as well as why it may be preferable to 
indomethacin will be supported. 
 
Definition and Description of the Problem 
 A ductus arteriosus (DA) is a bridge or canal connecting the pulmonary artery to the 
descending aorta during fetal life (Rowan & Grenville, 2004).  This opening is vital during fetal 
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circulation in order for a significant portion of the blood to bypass the pulmonary circulation and 
shunt to the body and eventually back to the placenta to be reoxygenated (Sekar & Corff, 2008).  
The placenta is considered the fetal lung during intrauterine life; therefore, only a small amount 
of circulating blood enters the pulmonary circulation during development.  During normal 
transition of a term infant from intrauterine to postnatal life, this ductus closes between 24-96 
hours of life as there is a decrease in pulmonary vascular resistance, smooth muscle constriction, 
decreased production of prostacylin and prostaglandin I2, increased production of endothelin 1, 
and an increase in acetylcholine and bradykinin (Toyer & Fox, 2004).  In addition, there are 
constricting properties of oxygen and an increase in this gas helps to constrict the ductus and 
begin apoptosis or cell death.   
The incidence of a persisting PDA can range from 10-60% of neonates inversely related 
to gestational age and birth weight (Dani et al., 2000).  In the premature infant, this closure may 
be delayed or non-existent for many reasons.  For instance, it can be that the pulmonary 
resistance does not decrease enough due to the premature infants lack surfactant, the production 
and/or secretion of hormones is not adequate to sustain ductal closure, or that premature neonates 
are less sensitive to the constricting properties of oxygen and more sensitive to the dilating 
properties of prostaglandins that remain in the circulation.  When the DA does not close 
postnatally, it produces left to right shunting of the blood as mentioned above due to the increase 
in systemic pressure and decrease in pulmonary vascular resistance (Linder et al., 2010).  This 
means the blood flowing from the left ventricle to the systemic circulation via the aorta, shunts 
across the patent ductus arteriosus back into the pulmonary circulation.  This shunting results in 
increase pulmonary blood flow and decreased systemic blood flow; therefore, less blood flow to 
other vital organs.  This can create very serious complications including, but not limited to, 
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pulmonary congestion, renal dysfunction, intraventricular hemorrhage (IVH), and 
gastrointestinal perforation resulting in necrotizing enterocolitis (NEC) (Heyman, 2003).  The 
figure below allows a visualization of where this shunting takes place.  
Fig. 1. Murphy, P.J. (2011). The Fetal Circulation 
 
 
Review of Evidenced-Based Literature 
 The databases used within the St. Catherine University Library website were: CINAHL, 
Medline, Cochrane review, and Google scholar.  Within these databases, the keywords: 
ibuprofen, neonatal population, and patent ductus arteriosis (PDA) were used.  The timeframe 
used in the search was 2000-2011.  Five single studies and two meta-analysis were chosen to be 
analyzed which compared indomethacin to ibuprofen in terms of their efficacy and adverse 
effects. 
The five single center studies reviewed all had similar purposes.  They were to compare 
the efficacy and safety of ibuprofen versus indomethacin in the treatment of the PDA in a 
neonate.  The efficacy was determined by whether or not the PDA closed with the appointed 
treatment.  Safety referred to the side effects or complications seen as a result of taking a 
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particular medication. Within the five articles being used to investigate this topic, two different 
research designs were seen.  Three studies used randomized control trials (RCTs) and examined 
the outcomes prospectively (Lago et al., 2002; Overmeire et al., 2000; Su et al., 2007), and two 
used retrospective comparative studies (Katakam et al., 2007; Linder et al., 2010).  RCTs are 
considered an experimental design, which is the strongest method to examine causality.  With 
these studies being conducted in an institution allows for more control over variables, increasing 
the validity of the results (Burns & Grove, 2009).  The studies used random assignment, 
spreading out the extraneous variables, adding to the validity of the results.  The retrospective 
comparative studies examined information in the charts of neonates whom had previously 
received either ibuprofen or indomethacin to measure effectiveness and safety.    
Power analysis was done in all of the RCTs, making the sample sizes appropriate in order 
to improve the external validity, making the results generalizable (Lago et al., 2002; Overmeire 
et al., 2000; Su et al., 2007).  In the retrospective study done by Linder et al. (2010), a power 
analysis was also performed validating the sample size, but it was not mentioned to have been 
done in the study conducted by Katakam et al. (2007).  By using inclusion and exclusion criteria 
along with random assignment increases the strength of the sampling strategy and 
generalizability of the findings.   
The independent variables or treatment in these studies are the medications: 
indomethacin and ibuprofen.  In all of the studies, the closure of the PDA was the primary 
dependent variable of concern.  Adverse effects and morbidities became additional dependent 
variables analyzed.  Some of the most frequent adverse effects seen were: decreased renal 
function, thrombocytopenia, increase in intraventricular hemorrhage (IVH), necrotizing 
enterocolitis (NEC), bronchopulmonary dysplasia (BPD), sepsis, increase length of stay, and 
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death.  The three RCTs used the same standard dosing amounts and schedules with each 
medication.  Using the same type, amount, and frequency of medication increases the validity 
and generalizability of the results.  All five studies used the same type of strategies to measure 
particular outcomes.  For example, they all used echocardiography to monitor the PDA, lab 
values to monitor renal function, thrombocytopenia, etc., and cranial ultrasounds to monitor for 
IVH, and so on.  This makes all of the study results very comparable.   
In the five single center studies conducted, there was no statistical significance in the 
closure of the PDA after receiving ibuprofen versus indomethacin.  However, in all of the 
literature, excluding the study conducted by Linder et al. (2010), there were statistically 
significant renal effects.  These studies found that indomethacin produced an increased incidence 
of oliguria (p = 0.017- p=0.13) and an increase in serum creatinine (p= 0.03 - p= 0.04).  In the 
study by Linder et al. (2010), indomethacin was also found to produce a statistically significant 
increase in thrombocytopenia (p < 0.007).  All other outcomes analyzed such as NEC, IVH, 
BPD, and mortality rates were found to be non-significant. 
After the five smaller studies were reviewed, two larger meta-analysis were reviewed.  
One analysis was by Thomas et al. (2004) comparing ibuprofen and indomethacin for the closure 
of the patent ductus arteriosus and the other analysis was a Cochrane review published by 
Ohlsson et al (2010) looking at “ibuprofen for the treatment of the patent ductus arteriosus in 
preterm and/or low birth weight infants.”  The first analysis was a compilation of nine studies, 
which found similar results of the previous single center studies.  That being that there was no 
statistical significant between the two medication for closing the PDA; however, there is 
statistically significant results in adverse effects as previously mentioned (Thomas et al., 2004).  
Five of these nine trials found a statistically significant increase in serum creatinine 
IBUPROFEN VS. INDOMETHACIN  
 
7 
concentration (p < 0.001), and statistically significant decreased urine output levels in the 
indomethacin group (p < 0.001).  This study also examined chronic lung disease as defined by 
neonates requiring oxygen after 28 days postnatally and found this to be a more common finding 
in the ibuprofen group (p < 0.05) (Thomas et al., 2004).  In this study, other adverse outcomes 
such as necrotizing enterocolitis, intraventricular hemorrhage, sepsis, retinopathy of prematurity, 
periventricular leukomalacia, and re-opening of the PDA were not found to be statistically 
significant. 
The Cochrane Collaboration meta-analysis conducted by Ohlsson et al. (2010) also 
compiled results from twenty different studies.  One of these studies compared ibuprofen to a 
placebo and not indomethacin, so these results will not be included.  The criteria for these studies 
were based on the type of study (randomized or quasi-randomized controlled trials), and the age 
or weight of the participants (preterm infants < 37 weeks gestation or low birth weight of < 2500 
grams) with a PDA confirmed by echocardiogram.  Once again, there were no statistically 
significant differences in the findings with regards to the closure of the PDA, mortality, need for 
surgical ligation, reopening of the ductus, ROP, IVH, sepsis, or length of hospital stay.  There 
was; however, statistical significance with regards to the incidence of decreased urine output in 
the indomethacin group (p = 0.006) and increase in serum creatinine (p < 0.01 – p = 0.07). 
 
Implications for Practice 
  The effects of a patent ductus arteriosus on a neonate can range from mild to severe 
effects.  The most likely event to occur if the ductus does not close on it’s own or with the help 
of a prostaglandin inhibiting medication or surgical ligation is that the pulmonary blood flow will 
become too much for the neonate to handle leading to a back up of blood into the heart creating 
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congestive heart failure (CHF) (Avery, 2005).  Once the baby has CHF, this can lead to 
numerous other complications and morbidities.   
The medical implications to discuss are the two statistically significant findings when 
using indomethacin instead of ibuprofen and those are decreased urine output (oliguria) and 
increased serum creatinine.  Decreased urine output can be a result of decreased renal blood 
flow, acute tubular necrosis, and/or nephron dysgenesis (Avery, 2005).  These are all negative 
effects on the renal system and could potentially create permanent renal damage.  The other 
negative effect, which was statistically significant, was an increase in serum creatinine.  Serum 
creatinine is used as a measure of the glomerular filtration rate (GFR) in the neonate.  GFR is a 
function of the kidney that correlates well with the gestational age of the child.  This means the 
lower the gestation, the lower the GFR and visa versa.  Giving indomethacin to preterm children 
with premature glomerular filtration rates places the neonate at a disadvantage and can lead to 
decreased urine output and decreased filtration of other substances of which would accumulate 
and become nephrotoxic. 
 
Parent Education 
 Parent education would be vital regarding the disease process, the available therapies, and 
potential adverse reactions in all scenarios.  The first topic of discussion would be regarding 
what a PDA is and why it is required during fetal life, but how it can create additional illnesses 
and complications if the ductus does not close postnatally.  Then, it would be important to 
support why there is a preference to first trial a medication versus the ligation even when there is 
not a guarantee of ductal closure and there are additional risks of side effects when giving the 
medication.  The next important discussion would be regarding what medication will be used and 
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why it is the preferred medication to a particular facility or providing practitioner.  Then with 
any medication being given, it would be important to discuss the potential adverse effects, which 
could occur.  After supporting a medication and thoroughly discussing the reasons behind giving 
it, it is also important to discuss the possibility of needing the surgical ligation if the medication 
did not produce the intended outcome. 
 
Conclusion 
There is sufficient evidence within the five individual studies and the two meta-analysis 
reviewed that substantiate the results that the two medications have similar outcomes with 
regards to closing the PDA.  However, there are statistically significant side effects, particularly 
effecting renal function when given indomethacin.  This side effect alone is a strong argument 
for a change in practice especially considering the population being neonates with already 
fragile, immature systems.  Given how ibuprofen produces less adverse effects, while producing 
similar ductal closure results, is a clinical indication that it should be used in place of 
indomethacin.   Knowing that facilities throughout the country continue to use indomethacin 
over ibuprofen when the two medications have comparable outcomes with ibuprofen producing 
fewer side effects is why this topic should be researched more extensively.  Providing these 
statistics and findings will be important in order to promote change in a field that cares for some 
of the most delicate patients.  
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